Literature DB >> 21228227

Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD.

Vjekoslav Tomaic1, David Pim, Miranda Thomas, Paola Massimi, Michael P Myers, Lawrence Banks.   

Abstract

Human papillomavirus (HPV) E6 oncoproteins target many cellular proteins for ubiquitin-mediated proteasomal degradation. In the case of p53, this is mediated principally by the E6AP ubiquitin ligase. Several studies have reported that E6 can target certain of its substrates in an apparently E6AP-independent fashion and that several of these substrates vary in the degree to which they are degraded by E6 at different stages of malignancy. To more fully understand the regulation of the E6AP/E6 proteolytic targeting complex, we performed a mass spectroscopic analysis of HPV type 18 (HPV-18) E6 protein complexes and identified the HECT domain-containing ubiquitin ligase EDD as a new HPV-18 E6 binding partner. We show that EDD can interact independently with both E6 and E6AP. Furthermore, EDD appears to regulate E6AP expression levels independently of E6, and loss of EDD stimulates the proteolytic activity of the E6/E6AP complex. Conversely, higher levels of EDD expression protect a number of substrates from E6-induced degradation, partly as a consequence of lower levels of E6 and E6AP expression. Intriguingly, reduction in EDD expression levels in HPV-18-positive HeLa cells enhances cell resistance to apoptotic and growth arrest stimuli. These studies suggest that changes in the levels of EDD expression during different stages of the viral life cycle or during malignancy could have a profound effect upon the ability of E6 to target various substrates for proteolytic degradation and thereby directly influence the development of HPV-induced malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228227      PMCID: PMC3067830          DOI: 10.1128/JVI.02004-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein.

Authors:  Helena Sterlinko Grm; Paola Massimi; Noor Gammoh; Lawrence Banks
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

2.  EDD mediates DNA damage-induced activation of CHK2.

Authors:  Michelle J Henderson; Marcia A Munoz; Darren N Saunders; Jennifer L Clancy; Amanda J Russell; Brandi Williams; Darryl Pappin; Kum Kum Khanna; Stephen P Jackson; Robert L Sutherland; Colin K W Watts
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

3.  Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators.

Authors:  V Tomaić; D Gardiol; P Massimi; M Ozbun; M Myers; L Banks
Journal:  Oncogene       Date:  2008-09-29       Impact factor: 9.867

4.  The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.

Authors:  Vjekoslav Tomaić; David Pim; Lawrence Banks
Journal:  Virology       Date:  2009-08-22       Impact factor: 3.616

Review 5.  Human papillomaviruses, cervical cancer and cell polarity.

Authors:  M Thomas; N Narayan; D Pim; V Tomaić; P Massimi; K Nagasaka; C Kranjec; N Gammoh; L Banks
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

6.  HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.

Authors:  P Massimi; A Shai; P Lambert; L Banks
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

7.  The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability.

Authors:  Robin M Vos; Jennifer Altreuter; Elizabeth A White; Peter M Howley
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.

Authors:  KyungWon Huh; Xiaobo Zhou; Hiroyuki Hayakawa; Je-Yoel Cho; Towia A Libermann; Jianping Jin; J Wade Harper; Karl Munger
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

9.  Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.

Authors:  S Camus; S Menéndez; C F Cheok; L F Stevenson; S Laín; D P Lane
Journal:  Oncogene       Date:  2007-01-15       Impact factor: 9.867

10.  Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase.

Authors:  Subbareddy Maddika; Junjie Chen
Journal:  Nat Cell Biol       Date:  2009-03-15       Impact factor: 28.824

View more
  28 in total

1.  UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells.

Authors:  Samantha A Swenson; Tyler J Gilbreath; Heather Vahle; R Willow Hynes-Smith; Jared H Graham; Henry C-H Law; Catalina Amador; Nicholas T Woods; Michael R Green; Shannon M Buckley
Journal:  Blood       Date:  2020-07-16       Impact factor: 22.113

Review 2.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

3.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 4.  The N-end rule pathway and regulation by proteolysis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

5.  The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.

Authors:  Jayashree Thatte; Paola Massimi; Miranda Thomas; Siaw Shi Boon; Lawrence Banks
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

6.  Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.

Authors:  Jayashree Thatte; Lawrence Banks
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

Review 7.  E3 ubiquitin ligases in B-cell malignancies.

Authors:  Jaewoo Choi; Luca Busino
Journal:  Cell Immunol       Date:  2019-02-26       Impact factor: 4.868

8.  PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.

Authors:  Nathaniel Edward Bennett Saidu; Vedrana Filić; Miranda Thomas; Vanessa Sarabia-Vega; Anamaria Đukić; Frane Miljković; Lawrence Banks; Vjekoslav Tomaić
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

9.  Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.

Authors:  Katia Zanier; Abdellahi ould M'hamed ould Sidi; Charlotte Boulade-Ladame; Vladimir Rybin; Anne Chappelle; Andrew Atkinson; Bruno Kieffer; Gilles Travé
Journal:  Structure       Date:  2012-04-03       Impact factor: 5.006

10.  E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60.

Authors:  V K Subbaiah; Y Zhang; D Rajagopalan; L N Abdullah; N S L Yeo-Teh; V Tomaić; L Banks; M P Myers; E K Chow; S Jha
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.